智通财经APP讯,首药控股(688197.SH)发布公告,公司近日通过国家药品监督管理局网站获悉,国家药品监督管理局批准公司完全自主研发的1类创新药康特替尼颗粒(CT-707,商品名:首要泽®)上市,该产品单药适用于既往未经过间变性淋巴瘤激酶(ALK)抑制剂治疗的ALK阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。
智通财经APP讯,首药控股(688197.SH)发布公告,公司近日通过国家药品监督管理局网站获悉,国家药品监督管理局批准公司完全自主研发的1类创新药康特替尼颗粒(CT-707,商品名:首要泽®)上市,该产品单药适用于既往未经过间变性淋巴瘤激酶(ALK)抑制剂治疗的ALK阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.